| Market Cap | 397.41M | P/E | - | EPS this Y | -12.10% | Ern Qtrly Grth | - |
| Income | -183.26M | Forward P/E | -3.30 | EPS next Y | 7.20% | 50D Avg Chg | 1.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 1.66 | EPS next 5Y | - | 52W High Chg | -44.00% |
| Recommedations | 1.70 | Quick Ratio | 6.39 | Shares Outstanding | 79.75M | 52W Low Chg | 32.00% |
| Insider Own | 2.20% | ROA | -40.64% | Shares Float | 50.06M | Beta | 0.94 |
| Inst Own | 104.27% | ROE | -89.09% | Shares Shorted/Prior | 12.69M/10.54M | Price | 7.32 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 331,548 | Target Price | 26.25 |
| Oper. Margin | - | Earnings Date | Aug 7 | Volume | 456,607 | Change | 6.86% |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| HC Wainwright & Co. | Buy | May 8, 24 |
| Truist Securities | Buy | Apr 3, 24 |
| Raymond James | Strong Buy | Mar 28, 24 |
| Piper Sandler | Overweight | Mar 26, 24 |
| Truist Securities | Buy | Mar 25, 24 |
| HC Wainwright & Co. | Buy | Mar 19, 24 |
| Jefferies | Buy | Oct 25, 23 |
| HC Wainwright & Co. | Buy | Oct 12, 23 |
| Wedbush | Outperform | Aug 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Myles Edward H | COO & CFO COO & CFO | Dec 29 | Sell | 19.16 | 12,459 | 238,714 | 168,784 | 12/29/23 |
| Myles Edward H | COO & CFO COO & CFO | Dec 29 | Option | 4.86 | 12,459 | 60,551 | 181,243 | 12/29/23 |
| Qatanani Mo | SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH | Dec 14 | Sell | 18.18 | 24,662 | 448,355 | 80,818 | 12/15/23 |
| Qatanani Mo | SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH | Dec 14 | Option | 10 | 8,437 | 84,370 | 105,480 | 12/15/23 |
| Myles Edward H | COO & CFO COO & CFO | Nov 02 | Sell | 12.5129 | 35,007 | 438,039 | 168,784 | 11/03/23 |
| AKKARAJU SRINIVAS | Director Director | Oct 16 | Buy | 6.85 | 2,189,781 | 15,000,000 | 6,788,609 | 10/18/23 |
| Samsara BioCapital GP, LLC | 10% Owner 10% Owner | Oct 16 | Buy | 6.85 | 2,189,781 | 15,000,000 | 6,788,609 | 10/18/23 |
| Invus Public Equities, L.P. | Director Director | Oct 12 | Buy | 7.7 | 2,199,931 | 16,939,469 | 11,259,438 | 10/16/23 |
| Qatanani Mo | SVP AND HEAD OF RESE.. SVP AND HEAD OF RESEARCH | Sep 18 | Sell | 6.34 | 1,945 | 12,331 | 97,043 | 09/20/23 |
| Invus Public Equities, L.P. | 10% Owner 10% Owner | Apr 28 | Buy | 6.4279 | 31,557 | 202,845 | 9,059,507 | 05/02/23 |
| Invus Public Equities, L.P. | 10% Owner 10% Owner | Jan 09 | Sell | 9.482 | 1,094 | 10,373 | 9,027,950 | 01/11/23 |
| Myles Edward H | Chief Financial Offi.. Chief Financial Officer | Nov 11 | Sell | 35.12 | 78,301 | 2,749,931 | 24,150 | 11/15/21 |